| Gene symbol | MIR132 | Synonyms | MIRN132, miRNA132, mir-132 | Type of gene | ncRNA |
| Chromosome | 17 | Map location | 17p13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | microRNA 132 | ||||
| GTO ID | GTC3519 |
| Trial ID | NCT05953831 |
| Disease | Heart Failure |
| Altered gene | MIR132 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | CDR132L |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy |
| Year | 2023 |
| Country | Germany |
| Company sponsor | Cardior Pharmaceuticals GmbH |
| Other ID(s) | CDR132L-P2-06 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||